Chilwa Minerals has debuted on Nasdaq following US$3.5M public offering
Get your Free Report on Top 5 ASX stocks for 2025
Chilwa Minerals Limited (ASX: CHW) announced on 01 October 2026 that it has raised US$3.5 million through an underwritten public offering of American Depositary Shares (ADS) ahead of its dual listing on Nasdaq.
The capital raising is comprised of 625,000 ADSs which are priced at US$5.60 each and each ADS represents 10 ordinary shares.Β Investors who participate will also receive one five year attaching warrant per ADS which will be exercisable at US$5.60. Underwriter Maxim Group LLC holds a 45 day overallotment option for up to an additional 92,000 ADSs and matching warrants.
Net proceeds are earmarked to advance mineral exploration activities, strengthen working capital and fund general corporate purposes while ordinary shares continue trading uninterrupted on the ASX.
Management noted that the U.S. listing provides access to North American capital focused on building critical mineral supply chains outside China. The cross listing also facilitates eligibility for U.S. government development grants to support assets in Malawi which will address western demand for heavy rare earths and gallium.
The expanded capital base will fund exploration across three key development streams within the Chilwa Critical Minerals Project including heavy mineral sands, ionic clay rare earths and the Nakombe niobium discovery featuring tantalum and gallium credits.
Chilwaβs directors and major shareholders have entered into six month voluntary lock up agreements covering 34,415,866 ordinary shares under an ASIC relief modification to support the transaction.
Chilwa's ADSs are scheduled to commence trading under the ticker symbol "CHWM" on the Nasdaq Capital Market on 1 October 2026 (New York time) marking the companyβs most significant capital milestone since its July 2023 ASX debut.
(Source: Company Announcements)
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether itβs appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
Feature News
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialRecent News
Cleo Diagnostics Expands IP Portfolio with Provisi..
Stakk Secures FBI Deployment for Signature Verific..
Rubicon Water Secures $12M Irrigation Modernisatio..
Memphasys Targets Fast-Track FDA Pathway for Felix..
Mesoblast Secures FDA Clearance for New Ryoncil Co..